FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

1. Name and Addres	ss of Reporting Perso	on*	2. Issuer Name and Ticker or Trading Symbol <u>FIBROGEN INC</u> [FGEN]		tionship of Reportin all applicable) Director) Perso X	n(s) to Issuer 10% Owner
(Last) C/O FIBROGEN 409 ILLINOIS S		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/19/2014	x	Officer (give title below) Chief Exect	ıtive C	Other (specify below) Officer
(Street) SAN FRANCISCO	СА	94158	4. If Amendment, Date of Original Filed (Month/Day/Year) 11/21/2014	6. Indiv Line) X	idual or Joint/Group Form filed by One Form filed by Mor Person	Report	ting Person
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	11/19/2014		С		60,946	A	(1)(2)	60,946	Ι	See footnote ⁽³⁾
Common Stock								3,843,162	D	
Common Stock								145,070	I	By Family Partnership
Common Stock								20,000	Ι	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock of Fibrogen Europe Oy	(2)	11/19/2014		С			1,052	(2)	(4)	Common Stock	770	(2)	0	Ι	See footnote ⁽⁵⁾

Explanation of Responses:

1. Each share of the issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.4 of a share of common stock immediately prior to the closing of the issuer's initial public offering, and has no expiration date.

2. Each share of the Fibrogen Europe Oy's Series A Preferred was automatically converted into into 0.732 of a share of common stock immediately prior to the closing of the issuer's initial public offering. 3. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

4. Not applicable.

5. The shares were held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

Remarks:

This form 4/A is being filed to add information that was omitted from the original form 4.

<u>/s/ Dorothy Pacini, Attorney-</u> <u>in-fact</u>

06/16/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.